MOLN: Molecular Partners Ltd Earnings per share for the last twelve months

Graphic logo of Molecular Partners Ltd (MOLN)

Risks for Molecular Partners AG (MOLN) are linked to the creation of innovative darpin proteins to combat viruses and cancer. This daily price chart of the annual EPS TTM on GURU.Markets helps assess stability, where the -1.69 mark characterizes this parameter. Business resilience is supported by alliances with pharma behemoths for the development of biologics and high demand for ophthalmology platforms, which expands the contract network.

MOLN molecularpartners.com Earnings per share for the last twelve months (07/04/2022 - 11/14/2026)

Molecular Partners (MOLN) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Quotes Molecular Partners AG|MOLN - Fair Value Consensus
- market capitalization information:
Market Value Molecular Partners Ltd|MOLN - Full Business Value
- shareholders' equity book value data:
Net Assets per Single Share Molecular Partners|MOLN - Company Book Value|Market Capitalization to Book Value Ratio molecularpartners.com|MOLN - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Molecular Partners AG|MOLN - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Molecular Partners AG|MOLN - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Molecular Partners AG|MOLN - Long-Term Debt|Company Short-Term Debt Molecular Partners|Quick Liquidity molecularpartners.com
- earnings and multiples data:
MOLN - Net Income|Expected Profit Molecular Partners AG|MOLN - Business Payback Period|Future Price to Earnings Molecular Partners Ltd|MOLN - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners AG|MOLN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Molecular Partners|MOLN - Earnings per share for the last twelve months|Quarterly EPS earnings growth molecularpartners.com|MOLN - Earnings per share growth rate in current year|Earnings growth forecast for next year Molecular Partners AG
- sales and revenue indicators:
MOLN - Company Sales|Company Future Sales Volume Molecular Partners Ltd|MOLN - P/S Multiple|Price-to-Projected Revenue Ratio Molecular Partners AG
Summary company analysis:MOLN - molecularpartners.com
Flagship merchandise of molecularpartners.com

The specifics of Molecular Partners AG (MOLN), featuring its DARPin platform and cost-sharing arrangements with pharma behemoths, directly impact the business's bottom-line profitability. This metric is calculated as the ratio of net income to the total number of shares, reflecting the actual earnings per share and allowing the annual net income per share trend to provide timely identification of the asset's fundamental value degradation or growth.

Main competitors

GERN: Net earnings per share for the last 12 months|Earnings per share for the trailing year NBTX (Nanobiotix SA)|Bicycle Therapeutics plc (BCYC) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months CTMX (CytomX Corp)|Earnings per share for the last twelve months Perspective Therapeutics|Earnings per share for the last twelve months GNLX|Net earnings per share (EPS TTM) ONCY|Net earnings per share (EPS TTM) Lisata (LSTA)|Moleculin Biotech - Net earnings per share for the last 12 months|Earnings per share for the last four quarters GRTX (Galera)|Molecular Templates Corp - Net earnings per share (EPS TTM)